Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2006Human Gene Therapy

Safety in Nonhuman Primates of Ocular AAV2- RPE65 , a Candidate Treatment for Blindness in Leber Congenital Amaurosis

View Full Paper
Ask AI
Bookmark
Share

Authors

Samuel G. JacobsonSamuel G. JacobsonUniversity of IowaSBSanford L. BoyeUniversity of Florida HealthTATomás S. AlemánChildren's Hospital of Philadelphia

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jacobson et al. (2006) studied this question.

synapsesocial.com/papers/6a70053178a11c550e09cfd6https://doi.org/10.1089/hum.2006.17.845
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal Injection2006 · 225 citations
  2. 2Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina1999 · 242 citations
  3. 3Anatomy and development of the macula: specialisation and the vulnerability to macular degeneration2005 · 200 citations
  4. 4Long-Term Restoration of Rod and Cone Vision by Single Dose rAAV-Mediated Gene Transfer to the Retina in a Canine Model of Childhood Blindness2005 · 480 citations
  5. 5Gene Replacement Therapy Rescues Photoreceptor Degeneration in a Murine Model of Leber Congenital Amaurosis Lacking RPGRIP2005 · 128 citations